C. Thompson

发表

Prevalence of familial malignancy in a prospectively screened cohort of patients with lymphoproliferative disorders

A. LaCasce, D. Neuberg, A. Freedman, 2008, British journal of haematology.

Diagnostic value of sentinel lymph node biopsy in head and neck cancer: a meta-analysis

C. J. Thompson, D. Elashoff, G. Lawson, 2013, European Archives of Oto-Rhino-Laryngology.

1.11 Integrative Genomic Analysis Implicates PIK3CA and MYC in Chronic Lymphocytic Leukemia

A. Regev, N. Pochet, D. Neuberg, 2011 .

A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL

D. Neuberg, J. Ritz, A. Freedman, 2010, Leukemia.

Obatoclax in combination with fludarabine and rituximab is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia

D. Neuberg, A. Freedman, D. Fisher, 2015, Leukemia & lymphoma.

Comparison of familial and sporadic chronic lymphocytic leukaemia using high resolution array comparative genomic hybridization

C. Ihm, Eun Kyung Cho, J. Tchinda, 2010, British journal of haematology.

Systematic genomic screen for tyrosine kinase mutations in CLL

D. Gilliland, R. Levine, A. Freedman, 2008, Leukemia.

Integrative Genomic Analysis Implicates Gain of PIK3CA at 3q26 and MYC at 8q24 in Chronic Lymphocytic Leukemia

A. Regev, N. Pochet, D. Neuberg, 2012, Clinical Cancer Research.

A Phase I Study of Lenalidomide in Combination with Fludarabine-Rituximab in Previously Untreated CLL/SLL.

D. Neuberg, J. Ritz, A. Freedman, 2009 .

Obatoclax in Combination with Fludarabine and Rituximab (FR) Is Well-Tolerated and Shows Promising Clinical Activity in Relapsed CLL/SLL

D. Neuberg, A. Freedman, D. Fisher, 2011 .

Integrative Genomic Analysis Implicates Gain of PIK3CA at 3q26 and MYC at 8q24 in Chronic Lymphocytic Leukemia

A. Regev, N. Pochet, D. Neuberg, 2012, Clinical Cancer Research.